Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Down 13.6% – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was down 13.6% during mid-day trading on Tuesday . The company traded as low as $8.79 and last traded at $8.79. Approximately 94,962 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 101,527 shares. The stock had previously closed at $10.17.

Wall Street Analyst Weigh In

SGIOY has been the topic of a number of recent analyst reports. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. Zacks Research cut Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The stock has a market cap of $16.49 billion, a P/E ratio of 11.69, a PEG ratio of 0.69 and a beta of 0.10. The company has a fifty day moving average of $10.47 and a 200 day moving average of $9.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%.The firm had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million. On average, equities analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.